Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    Roluperidone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minerva Neurosciences Updates Business, Reports Q2 Financial
    Minerva Neurosciences Updates Business, Reports Q2 Financial

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share
    Minerva's schizophrenia drug rejected by FDA for 2nd time
    Minerva's schizophrenia drug rejected by FDA for 2nd time

    28 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time

    FIERCE BIOTECH
    28 Feb 2024
    Share Share
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone

    10 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    10 May 2023
    Share Share
    Minerva Neurosciences Announces the NDA Filing for Roluperidone
    Minerva Neurosciences Announces the NDA Filing for Roluperidone

    01 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    01 May 2023
    Share Share
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone

    17 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    17 Oct 2022
    Share Share
    Minerva Submits New Drug Application to FDA for Roluperidone
    Minerva Submits New Drug Application to FDA for Roluperidone

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502130/32445/en/Minerva-Neurosciences-Submits-New-Drug-Application-to-FDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share